Published in Clin Cancer Res on November 01, 1997
Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol (2004) 5.29
Expression of vascular endothelial growth factor D is associated with hypoxia inducible factor (HIF-1alpha) and the HIF-1alpha target gene DEC1, but not lymph node metastasis in primary human breast carcinomas. J Clin Pathol (2004) 1.72
The emerging role of the LIV-1 subfamily of zinc transporters in breast cancer. Mol Med (2007) 1.51
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology (1991) 30.87
EGFR and cancer prognosis. Eur J Cancer (2001) 7.52
A prognostic index in primary breast cancer. Br J Cancer (1982) 7.35
Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med (1998) 6.86
The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat (1992) 6.51
Iron-chelation therapy with oral deferipronein patients with thalassemia major. N Engl J Med (1995) 3.88
Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol (2004) 3.80
Expression and amplification of cyclin genes in human breast cancer. Oncogene (1993) 3.79
Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk/NGF receptor gene. Nature (1994) 3.73
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol (2000) 3.33
Confirmation of a prognostic index in primary breast cancer. Br J Cancer (1987) 3.29
A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene (2006) 3.21
Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol (2003) 3.14
Factors influencing local recurrence after excision and radiotherapy for primary breast cancer. Br J Surg (1989) 2.84
Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology (1992) 2.75
Disruption of the neurotrophin-3 receptor gene trkC eliminates la muscle afferents and results in abnormal movements. Nature (1994) 2.61
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer (2001) 2.58
The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. Cell (1991) 2.56
Relationship of oestrogen-receptor status to survival in breast cancer. Lancet (1979) 2.55
Relationship between primary breast tumor receptor status and patient survival. Cancer (1980) 2.49
Neuroendocrine differentiation and prognosis in breast adenocarcinoma. Histopathology (2002) 2.35
Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia (2003) 2.28
Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol (2001) 2.21
A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. Hum Pathol (1995) 2.20
Sentinel node biopsy for breast cancer may have little to offer four-node-samplers. results of a prospective comparison study. Eur J Cancer (2001) 2.16
Why do women attend familial breast cancer clinics? J Med Genet (2000) 2.13
Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women. Breast Cancer Res Treat (2012) 2.05
Prevalence of haemochromatosis amongst asymptomatic Australians. Br J Haematol (1990) 2.01
Population genetics of modifiers of meiotic drive. I. The solution of a special case and some general implications. Theor Popul Biol (1973) 2.01
Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer (2004) 1.97
Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer (1989) 1.97
Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol (2006) 1.97
Detrimental haemodynamic effects of cyclizine in heart failure. Lancet (1988) 1.96
Estrogen receptor assay in primary breast cancer and early recurrence of the disease. Cancer Res (1978) 1.95
Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. Eur J Cancer (2007) 1.94
Randomized trial of a specialist genetic assessment service for familial breast cancer. J Natl Cancer Inst (2000) 1.92
Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer (2004) 1.91
Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst (1995) 1.91
Phyllodes tumours of the breast: a clinicopathological review of thirty-two cases. Histopathology (1995) 1.90
Relationship between oestrogen-receptor content and histological grade in human primary breast tumours. Br J Cancer (1978) 1.90
Histologic grading of breast cancer: linkage of patient outcome with level of pathologist agreement. Mod Pathol (2000) 1.88
Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer. Cancer Res (1990) 1.85
Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. Eur J Cancer (2013) 1.85
Reading the prognosis of the individual with breast cancer. Eur J Cancer (2007) 1.83
The psychological impact of immediate rather than delayed breast reconstruction. Eur J Surg Oncol (2000) 1.82
Screening interval breast cancers: mammographic features and prognosis factors. Radiology (1996) 1.82
Use of tumour marker immunoreactivity to identify primary site of metastatic cancer. BMJ (1993) 1.79
Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology (1994) 1.78
Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer (2005) 1.75
Prognostic factors in breast cancer -- the formation of a prognostic index. Clin Oncol (1979) 1.74
The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat (2011) 1.74
HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods. J Clin Pathol (2011) 1.73
Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax (2007) 1.73
X-ray refraction effects: application to the imaging of biological tissues. Br J Radiol (2003) 1.73
An integrated approach utilizing artificial neural networks and SELDI mass spectrometry for the classification of human tumours and rapid identification of potential biomarkers. Bioinformatics (2002) 1.73
Metabolism of 2,3,4,6-tetrachlorophenol by micro-organisms from broiler house litter. J Gen Microbiol (1974) 1.72
A monoclonal antibody, NCRC-11, raised to human breast carcinoma. 1. Production and immunohistological characterization. Histopathology (1984) 1.72
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer (2004) 1.72
Mechanism of activation of the vav protooncogene. Cell Growth Differ (1991) 1.71
Cytological grading of breast carcinoma--a feasible proposition? Cytopathology (1990) 1.70
A computer program to make linkage analysis with LIPED and LINKAGE easier to perform and less prone to input errors. Ann Hum Genet (1988) 1.70
Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis. Br J Cancer (2007) 1.66
Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer (2001) 1.65
Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res (1999) 1.65